Jean-gabriel G. Fuzibet

Nice, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study.

Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study.

Journal: American journal of hematology

Published: February 08, 2019

Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.

Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.

Journal: Leukemia

Published: October 05, 2018

Carfilzomib weekly 20/56 mg/m2 , lenalidomide and dexamethasone for early relapsed refractory multiple myeloma.

Carfilzomib weekly 20/56 mg/m2 , lenalidomide and dexamethasone for early relapsed refractory multiple myeloma.

Journal: American journal of hematology

Published: October 03, 2018

Limited Exercise Capacity in Patients with Systemic Sclerosis: Identifying Contributing Factors with Cardiopulmonary Exercise Testing.

Limited Exercise Capacity in Patients with Systemic Sclerosis: Identifying Contributing Factors with Cardiopulmonary Exercise Testing.

Journal: The Journal of rheumatology

Published: August 08, 2017

Severe intestinal obstruction due to Strongyloides stercoralis in a pregnant woman.

Severe intestinal obstruction due to Strongyloides stercoralis in a pregnant woman.

Journal: Medecine et maladies infectieuses

Published: August 01, 2016

Early detection of cardiac involvement in sarcoidosis with 2-dimensional speckle-tracking echocardiography.

Early detection of cardiac involvement in sarcoidosis with 2-dimensional speckle-tracking echocardiography.

Journal: International journal of cardiology

Published: July 28, 2016

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma.

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma.

Journal: Blood

Published: July 08, 2016

Tocilizumab-induced hypofibrinogenemia: A report of 7 cases.

Tocilizumab-induced hypofibrinogenemia: A report of 7 cases.

Journal: Joint bone spine

Published: February 01, 2016

BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice.

BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice.

Journal: The Journal of experimental medicine

Published: June 12, 2015

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.

Journal: Blood

Published: January 11, 2015

Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine.

Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine.

Journal: Blood cancer journal

Published: September 16, 2013

Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience.

Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 26, 2013

Showing 1-12 of 13

Last Updated: 09/26/2026